WO2004062690A1 - Nouveau procede d'isolement des endotoxines - Google Patents
Nouveau procede d'isolement des endotoxines Download PDFInfo
- Publication number
- WO2004062690A1 WO2004062690A1 PCT/FR2003/003617 FR0303617W WO2004062690A1 WO 2004062690 A1 WO2004062690 A1 WO 2004062690A1 FR 0303617 W FR0303617 W FR 0303617W WO 2004062690 A1 WO2004062690 A1 WO 2004062690A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- endotoxins
- mixture
- solvents
- composition
- chosen
- Prior art date
Links
- 239000002158 endotoxin Substances 0.000 title claims abstract description 65
- 238000000034 method Methods 0.000 title claims abstract description 60
- 239000000203 mixture Substances 0.000 claims abstract description 42
- 241000894006 Bacteria Species 0.000 claims abstract description 14
- 241001465754 Metazoa Species 0.000 claims abstract description 8
- 239000002904 solvent Substances 0.000 claims description 26
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 claims description 18
- 230000001580 bacterial effect Effects 0.000 claims description 16
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- 238000001914 filtration Methods 0.000 claims description 11
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 10
- 239000006228 supernatant Substances 0.000 claims description 10
- 238000005119 centrifugation Methods 0.000 claims description 9
- 239000000243 solution Substances 0.000 claims description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 8
- 239000007864 aqueous solution Substances 0.000 claims description 8
- 125000004432 carbon atom Chemical group C* 0.000 claims description 7
- 125000001931 aliphatic group Chemical group 0.000 claims description 6
- 239000002245 particle Substances 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 229910021529 ammonia Inorganic materials 0.000 claims description 5
- 238000000502 dialysis Methods 0.000 claims description 5
- 241000588832 Bordetella pertussis Species 0.000 claims description 4
- 239000012228 culture supernatant Substances 0.000 claims description 4
- 239000000706 filtrate Substances 0.000 claims description 4
- 229960005486 vaccine Drugs 0.000 claims description 4
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 claims description 3
- 239000000284 extract Substances 0.000 claims description 3
- 239000000047 product Substances 0.000 claims description 3
- 238000011084 recovery Methods 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- 241000588780 Bordetella parapertussis Species 0.000 claims description 2
- 241000588724 Escherichia coli Species 0.000 claims description 2
- 241000606790 Haemophilus Species 0.000 claims description 2
- 241000588653 Neisseria Species 0.000 claims description 2
- 241000589516 Pseudomonas Species 0.000 claims description 2
- 241000607142 Salmonella Species 0.000 claims description 2
- 241000607768 Shigella Species 0.000 claims description 2
- 238000001556 precipitation Methods 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims 1
- 238000000605 extraction Methods 0.000 description 14
- 229920006008 lipopolysaccharide Polymers 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 9
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 239000000356 contaminant Substances 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 3
- -1 aliphatic amines Chemical class 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 150000004676 glycans Polymers 0.000 description 2
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 150000003904 phospholipids Chemical group 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 241000588807 Bordetella Species 0.000 description 1
- 241001646716 Escherichia coli K-12 Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 108090001030 Lipoproteins Chemical group 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- UMFQPQLYSOSXSB-UHFFFAOYSA-N azanium;2-methylpropanoic acid;hydroxide Chemical compound [NH4+].O.CC(C)C([O-])=O UMFQPQLYSOSXSB-UHFFFAOYSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 210000005256 gram-negative cell Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 150000005605 isobutyric acids Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000004853 microextraction Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- KSSNXJHPEFVKHY-UHFFFAOYSA-N phenol;hydrate Chemical compound O.OC1=CC=CC=C1 KSSNXJHPEFVKHY-UHFFFAOYSA-N 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000012465 retentate Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
- C12P1/04—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the subject of the invention is a new process for extracting endotoxins from bacteria, in particular Gram-negative bacteria, as well as the use of this process for the preparation of compositions comprising endotoxins or their derivatives and intended for human or animal use (scientific, medical ).
- Endotoxins are powerful stimulants of the immune system (induction of Interleukins. TNF, NO ). They are the main constituents of the outer membranes of Gram-negative bacteria. Endotoxins are mixtures of lipopolysaccharides or LPS. Among the bacterial colonies, there are mainly two categories: those called type S, for "smooth”, relating to the smooth appearance of the colony; those called type R, for “rough”, this term recalling the rough morphology of the colony. There is also a third category called SR for “semi- rough”. The structure of the LPS constituents of bacterial endotoxins is different depending on whether they are type R or S bacteria. The LPS consist of a lipid domain called lipid A and of a polysaccharide chain, called nucleus, attached to the lipid A.
- LPS type S also has an antigenic chain called type O.
- LPS type R does not have this antigenic chain type O.
- LPS type SR has a single unit of the antigenic chain type O.
- the present invention relates more particularly to the isolation of endotoxins from a bacterial culture of type R and optionally of type S-R. However, it can also be applied to bacterial cultures of type S.
- the bacterial endotoxins were isolated by extraction using a mixture of solvents which could be a mixture of phenol and water or a mixture of chloroform, petroleum ether and phenol. These methods have the serious disadvantage of using toxic solvents and therefore entail health risks for the people who have to handle them. There is also a method of extraction with trichloroacetic acid, however this method causes too much contamination to be considered satisfactory.
- This document also describes a method for purifying natural endotoxins from isolated endotoxins according to one of the traditional methods of phenol extraction in a first step.
- the endotoxins are purified by extraction using the mixture of solvents isobutyric acid / molar NH OH (5: 3).
- the extract is centrifuged and the supernatant recovered.
- the solvents are evaporated.
- the endotoxin is recovered by trituration with ethanol.
- the method according to the invention is characterized in that: - the starting product is a set of bacterial cells, or optionally a culture supernatant; - in a first step, the bacterial cells, or the culture supernatant, are suspended in a mixture of solvents consisting of:
- the solvents are removed from the supernatant or the filtrate by any means known to those skilled in the art, such as in particular: dialysis, filtration / washing, precipitation of LPS, for example by addition of ethanol.
- the method according to the present invention has many advantages over the methods of the prior art. It is fast: the extraction of endotoxins takes 12 to 24 hours or less, while in phenol extraction processes, the extraction stage itself lasted at least a week.
- This method does not use silica, it is simpler to implement, especially on an industrial scale. This method does not use toxic solvents, so it is not dangerous for the manipulators who use it. She is very selective.
- the yields are 2 to 10 times higher than those obtained by the methods of the prior art for the bacteria already tested.
- the LPS obtained by the process of the invention have the advantage of not being a carrier of contaminants.
- Aliphatic acids comprising 4 carbon atoms are preferred, such as butyric and iso-butyric acids.
- the aliphatic acid preferentially used in the present invention is iso-butyric acid.
- aliphatic amines which can be used in the present invention, there may be mentioned in particular: ammonia, dusopropylethylamine, triethylamine.
- ammonia or triethylamine are chosen.
- Aliphatic amines are used in aqueous solution with a concentration ranging from 5 to 20%, preferably with a concentration around 10%.
- composition resulting from the first step is a heterogeneous composition comprising on the one hand particles of suspended cellular debris, on the other hand the bacterial endotoxins in solution in the mixture of solvents.
- the composition obtained from the third step of the process of the invention can be extracted (dialysate or precipitated LPS which is taken up in water) using methanol or a mixture of chloroform and methanol to remove, in particular, contaminating phospholipid or lipoprotein residues.
- the endotoxins obtained from the process of the invention can be kept in aqueous solution or lyophilized in order to store them in powder form, the latter solution having the advantage of facilitating their handling and their dosage.
- the bacterial cells used as starting material are preferably Gram negative cells.
- Cells preferably used in the process of the invention are: Bordetella pertussis, Escherichia Coli, Bordetella parapertussis, Salmonella, Shigella, Pseudomonas, Neisseria, Haemophilus.
- the bacterial cells are generally obtained by centrifugation of a culture medium and recovery of the bacterial pellet. However, during this centrifugation operation, it is possible to recover a supernatant which can be rich in lipopolysaccharides and can constitute a starting product for the application of the method of the invention.
- the preferred solvent mixtures are: isobutyric acid and either ammonia in aqueous molar solution or triethylamine in 10% aqueous solution (percentage by volume).
- a mixture of isobutyric acid and ammonia in aqueous molar solution is used in a volume ratio 5/3 or a mixture of isobutyric acid and triethylamine in aqueous solution at 10% in a volume ratio 5/3 .
- the agitation corresponding to the first step of the process of the invention lasts from 5 to 15 minutes. Even more advantageously from 10 to 15 minutes.
- the filtration is made on a support with a porosity ranging from 0.1 to 2 ⁇ m.
- this centrifugation is preferably carried out under the following conditions: 1500 to 3000 g, for 10 to 20 minutes at room temperature. Preferably 2000g for about 15 minutes.
- the method according to the present invention allows endotoxins to be obtained quickly, with very good yields and substantially free of biological contaminants or solvents. All these properties make it possible to envisage applications which until then could hardly be implemented.
- compositions intended for human or animal administration Due to the toxicity of the solvents used in the prior art and the purification difficulties which they entailed, such applications were not conceivable. Thanks to the process of the invention, it is now possible to prepare compositions, in particular therapeutic compositions, which can be administered to humans or to animals (subject to the non-toxicity of the molecules themselves) by all routes: oral, injection, application to the skin or mucous membranes.
- vaccine compositions comprising endotoxins, or endotoxin derivatives, on an industrial scale.
- endotoxin derivatives mention may in particular be made of detoxified endotoxins, endotoxin fragments, endotoxins conjugated with other molecules, in particular with proteins.
- endotoxins to prepare vaccine compositions is cited in particular in EP-976402.
- the invention therefore also relates to a process for the preparation of a composition comprising one or more endotoxins or derivatives of endotoxins, such as in particular endotoxin fragments, detoxified endotoxins, intended for human or animal administration, characterized in that it includes a step of isolating endotoxins as described above.
- the isolated endotoxins are incorporated into an appropriate vehicle, in particular a pharmaceutically acceptable vehicle. They can also be packaged directly for an extemporaneous preparation of the composition intended for human or animal administration.
- lyophilized cells or the equivalent of wet bacterial pellet
- the mixture is centrifuged at 2000 g for 15 minutes at room temperature.
- the clarified supernatant, containing the endotoxin is filtered on sandpaper (Whatman GF / D), diluted with three volumes of distilled water and dialysis. A second extraction of the pellet can be carried out if necessary.
- the dialysis retentate is filtered on sandpaper under the same conditions as above, then lyophilized, and it is extracted with a mixture of chloroform and methanol (1: 2) to remove any phospholipid contaminants.
- the residue from the extraction is then lyophilized.
- the two filtration steps can be carried out on sintered glass (16-40 ⁇ m) covered with sandpaper and a partial vacuum can be applied to speed up the process subject to quality control of the filtrate on TLC.
- the yield is 2 to 10%> depending on the bacteria.
- the extraction is carried out in 24 hours. This duration can be further reduced to a few hours by filtration dialysis methods, applicable on an industrial scale.
- the bacteria When the bacteria contain capsular polysaccharides in large quantities, it may be advantageous to eliminate them by washing the cells before carrying out the extraction.
- FIG. 1 represents a comparative thin layer chromatography of the endotoxins isolated by these two methods.
- SDS-PAGE gel, TLC and mass spectrometry made it possible to verify the effectiveness of the method and the integrity of the endotoxins.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK03815086.8T DK1578442T3 (da) | 2002-12-09 | 2003-12-08 | Fremgangsmåde til isolering af endotoxiner |
AU2003296775A AU2003296775A1 (en) | 2002-12-09 | 2003-12-08 | Novel method for isolating endotoxins |
CA2513813A CA2513813C (fr) | 2002-12-09 | 2003-12-08 | Procede d'isolement de lipopolysaccharides |
ES03815086T ES2397516T3 (es) | 2002-12-09 | 2003-12-08 | Procedimiento de aislamiento de endotoxinas |
EP03815086A EP1578442B1 (fr) | 2002-12-09 | 2003-12-08 | Procédé d'isolement d'endotoxines. |
US10/542,090 US8137935B2 (en) | 2002-12-09 | 2003-12-08 | Method for isolating endotoxins |
US13/368,697 US20120213821A1 (en) | 2002-12-09 | 2012-02-08 | Novel method for isolating endotoxins |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0215555A FR2848223B1 (fr) | 2002-12-09 | 2002-12-09 | Nouveau procede d'isolement des endotoxines. |
FR0215555 | 2002-12-09 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/368,697 Division US20120213821A1 (en) | 2002-12-09 | 2012-02-08 | Novel method for isolating endotoxins |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004062690A1 true WO2004062690A1 (fr) | 2004-07-29 |
Family
ID=32320125
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2003/003617 WO2004062690A1 (fr) | 2002-12-09 | 2003-12-08 | Nouveau procede d'isolement des endotoxines |
Country Status (8)
Country | Link |
---|---|
US (2) | US8137935B2 (fr) |
EP (1) | EP1578442B1 (fr) |
AU (1) | AU2003296775A1 (fr) |
CA (1) | CA2513813C (fr) |
DK (1) | DK1578442T3 (fr) |
ES (1) | ES2397516T3 (fr) |
FR (1) | FR2848223B1 (fr) |
WO (1) | WO2004062690A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1974720A1 (fr) | 2007-03-26 | 2008-10-01 | L'Oreal | Utilisation d'une fraction lipopolysaccharidique de vitreoscilla filiformis comme agent stimulant la synthese de peptides antimicrobiens de la peau |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2848223B1 (fr) * | 2002-12-09 | 2005-02-25 | Centre Nat Rech Scient | Nouveau procede d'isolement des endotoxines. |
CN101646693B (zh) * | 2007-02-28 | 2013-03-27 | 利普生技术有限公司 | 降低多聚唾液酸中的内毒素 |
FI20085812A0 (fi) * | 2008-09-01 | 2008-09-01 | Esa-Matti Lilius | Karkea LPS immunostimulanttina vesiviljelyssä |
PL212286B1 (pl) | 2010-06-20 | 2012-09-28 | Inst Immunologii I Terapii Doswiadczalnej Pan | Sposób otrzymywania bakteriofagów |
PL218313B1 (pl) | 2010-10-28 | 2014-11-28 | Inst Immunologii I Terapii Doświadczalnej Pan | Kompetytywna metoda otrzymywania preparatów bakteriofagowych |
US9598504B2 (en) * | 2014-12-16 | 2017-03-21 | Chitogen Inc. | Process for the removal of endotoxins to produce medical quality chitosan and other polysaccharides |
GB201703261D0 (en) * | 2017-02-28 | 2017-04-12 | Imp Innovations Ltd | Method of detection |
KR20230074410A (ko) | 2020-03-13 | 2023-05-30 | 헤파이스토스-파마 | 해독된 지질다당류(lps), 천연 무독성 lps, 및 이의 용도 |
CN112898443B (zh) * | 2021-01-28 | 2022-11-04 | 苏州微超生物科技有限公司 | 菌体中脂寡糖和寡糖的提取纯化方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0976402A2 (fr) * | 1998-07-29 | 2000-02-02 | Biosynth S.R.L. | Vaccins pour la prévention d' infections à bactéries gram-négatifs et de maladies dues aux endotoxines |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3328253A (en) * | 1965-04-15 | 1967-06-27 | Watanabe Yoshikazu | Process for the production and purification of ogawa lipopolysaccharide cholera antigen |
FR2393065A1 (fr) * | 1977-05-31 | 1978-12-29 | Merieux Inst | Procede de separation de lipides d'endotoxines bacteriennes et notamment d'endotoxine de bordetella pertussis |
US4663306A (en) * | 1983-09-23 | 1987-05-05 | Ribi Immunochem Research, Inc. | Pyridine-soluble extract-refined detoxified endotoxin composition and use |
CA1212051A (fr) * | 1984-03-02 | 1986-09-30 | John W. Cherwonogrodzky | Identification de brucella abortus et de la brucellose |
US5169535A (en) * | 1989-09-22 | 1992-12-08 | Kurita Water Industries Ltd. | Method of removing endotoxin |
US5391715A (en) * | 1989-11-06 | 1995-02-21 | Smithkline Beecham Biologicals | Method for isolating and purifying bordetella pertussis antigenic factors |
US5824310A (en) * | 1991-10-22 | 1998-10-20 | The United States Of America As Represented By The Department Of Health And Human Services | Lipopplysaccharide conjugate vaccines |
DE4331358A1 (de) * | 1992-10-12 | 1994-04-14 | Braun Melsungen Ag | Verfahren zur quantitativen selektiven Entfernung oder präparativen Gewinnung von Tumor-Nekrose-Faktor (TNF) oder/und Lipopolysacchariden (LPS) aus wäßrigen Flüssigkeiten |
DE19515554C2 (de) * | 1995-04-27 | 1999-06-17 | Braun Melsungen Ag | Verwendung eines Mittels und Vorrichtung zur simultanen extrakorporalen Elimination von Tumor-Nekrose-Faktor alpha und bakteriellen Lipopolysacchariden aus Vollblut oder/und Blutplasma |
US6106723A (en) * | 1997-02-10 | 2000-08-22 | Grandics; Peter | Method for removing pyrogens from dialysate |
US6482584B1 (en) * | 1998-11-13 | 2002-11-19 | Regeneration Technologies, Inc. | Cyclic implant perfusion cleaning and passivation process |
WO2000037172A1 (fr) * | 1998-12-22 | 2000-06-29 | Toray Industries, Inc. | Materiaux destines a l'elimination de composants bacteriens |
GB9910807D0 (en) * | 1999-05-10 | 1999-07-07 | Prometic Biosciences Limited | Novel detoxification agents and their use |
US6774102B1 (en) * | 1999-09-29 | 2004-08-10 | Gambro Dialysatoren Gmbh & Co. Kg | Extracorporeal endotoxin removal method |
DE10010342A1 (de) * | 2000-03-06 | 2001-09-20 | Merck Patent Gmbh | Verfahren zur Abreicherung von Endotoxinen |
US20030031684A1 (en) * | 2001-03-30 | 2003-02-13 | Corixa Corporation | Methods for the production of 3-O-deactivated-4'-monophosphoryl lipid a (3D-MLA) |
FR2848223B1 (fr) * | 2002-12-09 | 2005-02-25 | Centre Nat Rech Scient | Nouveau procede d'isolement des endotoxines. |
JP5017848B2 (ja) * | 2005-11-25 | 2012-09-05 | Jnc株式会社 | エンドトキシン吸着体、およびそれを用いたエンドトキシンの除去方法 |
PL217758B1 (pl) * | 2008-09-29 | 2014-08-29 | Inst Immunologii I Terapii Doświadczalnej Pan | Sposób otrzymywania złoża do chromatografii powinowactwa i zastosowanie otrzymanego tym sposobem złoża |
-
2002
- 2002-12-09 FR FR0215555A patent/FR2848223B1/fr not_active Expired - Fee Related
-
2003
- 2003-12-08 US US10/542,090 patent/US8137935B2/en active Active
- 2003-12-08 AU AU2003296775A patent/AU2003296775A1/en not_active Abandoned
- 2003-12-08 EP EP03815086A patent/EP1578442B1/fr not_active Expired - Lifetime
- 2003-12-08 CA CA2513813A patent/CA2513813C/fr not_active Expired - Lifetime
- 2003-12-08 ES ES03815086T patent/ES2397516T3/es not_active Expired - Lifetime
- 2003-12-08 DK DK03815086.8T patent/DK1578442T3/da active
- 2003-12-08 WO PCT/FR2003/003617 patent/WO2004062690A1/fr not_active Application Discontinuation
-
2012
- 2012-02-08 US US13/368,697 patent/US20120213821A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0976402A2 (fr) * | 1998-07-29 | 2000-02-02 | Biosynth S.R.L. | Vaccins pour la prévention d' infections à bactéries gram-négatifs et de maladies dues aux endotoxines |
Non-Patent Citations (5)
Title |
---|
CAROFF M G L ET AL: "SEVERAL USES FOR ISOBUTYRIC ACID-AMMONIUM HYDROXIDE SOLVENT IN ENDOTOXIN ANALYSIS", APPLIED AND ENVIRONMENTAL MICROBIOLOGY, vol. 56, no. 6, 1990, pages 1957 - 1959, XP008024672, ISSN: 0099-2240 * |
DI FABIO J I ET AL: "Characterization of the common antigenic lipopolysaccharide O-chains produced by Bordetella bronchiseptica and Bordetella parapertussis", FEMS (FEDERATION OF EUROPEAN MICROBIOLOGICAL SOCIETIES) MICROBIOLOGY, vol. 97, no. 3, 1992, 1992, pages 275 - 281, XP008024673, ISSN: 0378-1097 * |
H. THERISOD ET AL: "Direct Microextraction and analysis of rough type Lipopolysaccharides by combined thin-layer Chromatography and MALDI spectrometry", ANALYTICAL CHEMISTRY, vol. 73, no. 16, 15 August 2001 (2001-08-15), pages 3804 - 3807, XP002262340 * |
RIDLEY BRENT L ET AL: "The type and yield of lipopolysaccharide from symbiotically deficient Rhizobium lipopolysaccharide mutants vary depending on the extraction method", GLYCOBIOLOGY, vol. 10, no. 10, October 2000 (2000-10-01), pages 1013 - 1023, XP008024739, ISSN: 0959-6658 * |
VALVERDE CLAUDIO ET AL: "Rapid preparation of affinity-purified lipopolysaccharide samples for electrophoretic analysis", BIOTECHNIQUES, vol. 22, no. 2, 1997, pages 230, 232, 234, 236, XP001160910, ISSN: 0736-6205 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1974720A1 (fr) | 2007-03-26 | 2008-10-01 | L'Oreal | Utilisation d'une fraction lipopolysaccharidique de vitreoscilla filiformis comme agent stimulant la synthese de peptides antimicrobiens de la peau |
Also Published As
Publication number | Publication date |
---|---|
US8137935B2 (en) | 2012-03-20 |
FR2848223B1 (fr) | 2005-02-25 |
FR2848223A1 (fr) | 2004-06-11 |
EP1578442A1 (fr) | 2005-09-28 |
CA2513813C (fr) | 2013-04-02 |
AU2003296775A1 (en) | 2004-08-10 |
US20120213821A1 (en) | 2012-08-23 |
ES2397516T3 (es) | 2013-03-07 |
AU2003296775A8 (en) | 2004-08-10 |
EP1578442B1 (fr) | 2012-10-24 |
US20070020292A1 (en) | 2007-01-25 |
CA2513813A1 (fr) | 2004-07-29 |
DK1578442T3 (da) | 2013-02-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20120213821A1 (en) | Novel method for isolating endotoxins | |
EP1124835B1 (fr) | Application de fuco-oligosaccharides sulfates a la protection des plantes | |
CA2804480A1 (fr) | Complexe macromoleculaire d'origine bacterienne et utilisation dudit complexe macromoleculaire pour prevenir et traiter les rhumatismes inflammatoires | |
EP0013851A1 (fr) | Protéoglycanes bactériens purifiés, procédé pour leur préparation et vaccin les contenant | |
EP0049182A1 (fr) | Nouvelles glycoprotéines immunostimulantes extraites de Klebsiella Pneumoniae, leur procédé d'obtention, leur application à titre de médicaments et les compositions les renfermant | |
EP0179679B1 (fr) | Polysaccharides membranaires utiles notamment comme médicament et procédé pour leur préparation | |
EP0089266B2 (fr) | Procédé de préparation de protéoglycanes immunostimulants inducteurs d'interféron, protéoglycanes obtenus et médicament les contenant | |
JPH06507077A (ja) | 細菌高分子の抽出物、その調製のための方法及び前記抽出物を含む製薬組成物 | |
CH639396A5 (fr) | Substance dite ''ks-2-b'' et procede pour sa fabrication. | |
EP0485577B1 (fr) | Medicament immunostimulant a base de glycopeptidolipides polaires de mycobacterium chelonae | |
CH662056A5 (fr) | Procede de purification de polyosides de streptococcus pneumoniae et vaccin a base de polyosides ainsi purifies. | |
FR2990696A1 (fr) | Souche productrice de turanose et utilisations | |
CH639395A5 (fr) | Glycoproteines constitutives d'hafnia, procede de preparation et compositions pharmaceutiques. | |
FR2476127A1 (fr) | Nouvel antibiotique et son procede de preparation par culture d'une souche actinomadura | |
CH669386A5 (fr) | ||
CH663033A5 (fr) | Substance-melange dite ''spf-100'' et procede pour sa preparation. | |
EP1352053A2 (fr) | Procede de maturation des cellules dendritiques et d'activation des macrophages avec le ru 41740 | |
FR2536280A1 (fr) | Composition pharmaceutique et procede pour le traitement de tumeurs | |
FR2499855A1 (fr) | Nouvelles substances a action carcinostatique et immuno-stimulante, procede pour les preparer a partir de bacteries du genre fusobacterium, et agent carcinostatique contenant de telles substances | |
FR2531863A1 (fr) | Procede de preparation d'une substance ayant une activite carcinostatique et immunostimulante, a partir de micro-organismes du genre fusobacterium | |
WO2004007540A1 (fr) | Extraits membranaires de klebsiella presentant des proprietes avantageuses, et procede de production de ces extraits | |
CA2123587A1 (fr) | Produit bactericide, composition pharmaceutique le contenant et additif alimentaire | |
FR2526027A1 (fr) | Procede pour la purification de dimycolates et trehalose brut (tdm) et produit ainsi obtenu | |
BE566435A (fr) | ||
FR3089231A1 (fr) | procédé d’obtention d’une solution aqueuse enrichie en pigment bleu |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003815086 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2513813 Country of ref document: CA |
|
WWP | Wipo information: published in national office |
Ref document number: 2003815086 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007020292 Country of ref document: US Ref document number: 10542090 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |
|
WWP | Wipo information: published in national office |
Ref document number: 10542090 Country of ref document: US |